Regulatory role of natural killer T cells in diabetes by Tard, Celine et al.
w.sciencedirect.com
b i om e d i c a l j o u r n a l 3 8 ( 2 0 1 5 ) 4 8 4e4 9 5Available online at wwScienceDirect
Biomedical Journal
journal homepage: www.elsevier .com/locate/bjReview Article: Special EditionRegulatory role of natural killer T cells in
diabetesCeline Tard a,b,c,d, Ophelie Rouxel a,b,c,d, Agnes Lehuen a,b,c,d,*
a Laboratory “Immunology of Diabetes”, U1016 INSERM-Institut Cochin, Paris, France
b CNRS UMR8104, Paris, France
c Laboratoire d'Excellence INFLAMEX, Universite Paris Descartes, Sorbonne Paris Cite, Paris, France
d DHU Authors, Ho^pital Cochin, 75014, Paris, Francea r t i c l e i n f o
Article history:
Received 4 November 2014
Accepted 24 April 2015
Available online 10 March 2016
Keywords:
Autoimmunity
Diabetes
Immune regulation
Metabolism
NKT* Corresponding author. Laboratory “Immuno
France. Tel.: þ33 1 76535590; fax: þ33 1 4634
E-mail address: Agnes.Lehuen@inserm.fr
Peer review under responsibility of Chan
http://dx.doi.org/10.1016/j.bj.2015.04.001
2319-4170/Copyright © 2016, Chang Gung Un
the CC BY-NC-ND license (http://creativecoma b s t r a c t
Type 1 and type 2 diabetes are growing public health problems. Despite having different
pathophysiologies, both diseases are associated with defects in immune regulation.
Invariant natural killer T (iNKT) cells are innate-like T cells that recognize glycolipids
presented by CD1d. These cells not only play a key role in the defense against pathogens,
but also exert potent immunoregulatory functions. The regulatory role of iNKT cells in the
prevention of type 1 diabetes has been demonstrated in murine models and analyzed in
diabetic patients. The decreased frequency of iNKT cells in non-obese diabetic mice
initially suggested the regulatory role of this cell subset. Increasing the frequency or the
activation of iNKT cells with agonists protects non-obese diabetic mice from the devel-
opment of diabetes. Several mechanisms mediate iNKT regulatory functions. They can
rapidly produce immunoregulatory cytokines, interleukin (IL)-4 and IL-10. They induce
tolerogenic dendritic cells, thereby inducing the anergy of autoreactive anti-islet T cells
and increasing the frequency of T regulatory cells (Treg cells). Synthetic agonists are able to
activate iNKT cells and represent potential therapeutic treatment in order to prevent type 1
diabetes. Growing evidence points to a role of immune system in glucose intolerance and
type 2 diabetes. iNKT cells are resident cells of adipose tissue and their local and systemic
frequencies are reduced in obese patients, suggesting their involvement in local and sys-
temic inflammation during obesity. With the discovery of potential continuity between
type 1 and type 2 diabetes in some patients, the role of iNKT cells in these diseases de-
serves further investigation.Type 1 diabetes (T1D) is an autoimmune disease characterized 80% of the b-cells are destroyed, the consecutive lack of in-by the selective destruction of pancreatic islet b-cells, in the
context of an underlying multigenetic inheritance [1]. Whenlogy of Diabetes,” U1016
6454.
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adaptive immune systems; both are inappropriately activated
by a triggering event, initiating an immune cascade that re-
sults in loss of self-tolerance and islet destruction [2,3]. T1D is
a typical Th1 cell-mediated autoimmune disease character-
ized by the presence of autoreactive anti-islet T cells, which
play a prominent role in the development of the disease [4].
Autoreactive B cells produce autoantibodies targeting b-cell
antigens, and could act as antigen-presenting cells (APCs), but
have a limited role in the pathophysiology. The emergence of
diabetogenic T cells appears to be associated with defective
immunoregulation [5]. Numerical and functional deficiencies
of CD4þ FoxP3þ T regulatory (Treg) cells have been demon-
strated in T1D [6,7]. However, Treg cells do not account for the
entire regulatory functions; another regulatory T cell subset,
invariant natural killer T (iNKT) cells, has also been demon-
strated to be involved in the pathophysiology of the disease.
Type 2 diabetes (T2D) accounts for over 90% of the diag-
nosed cases of diabetes. It is a heterogeneous disorder char-
acterized by peripheral insulin resistance, impaired regulation
of hepatic glucose production, and b-cell dysfunction. T2D is
frequently associated with obesity or overweight, and insulin
resistance could bemostly secondary to the coexistence of this
increased adiposity [8,9]. If insulin resistance is present, the b-
cells increase insulin output in order to maintain glucose ho-
meostasis. When the b-cells cannot release sufficient insulin,
blood glucose concentration rises, leading to glucose intoler-
ance and T2D. As in T1D, genetic factors and environment
interact in the development of the disease. In contrast to T1D,
genome-wide association studies found that most of the genes
implicated in T2D are linked to b-cell function, whereas genes
associated with an increased risk of T1D mostly involve the
immune system. A link between obesity, systemic inflamma-
tion, and metabolic complications has been proposed for de-
cades [9]. Recent studies demonstrated that metabolism and
the immune system are strongly associated in the develop-
ment of obesity-dependent insulin resistance, where both
innate and adaptive immune systems play a role.
In this review, we will discuss the role of NKT cells in the
pathophysiology of T1D and T2D: protective, pathologic, and
still partially mysterious.iNKT cells
NKT cells are a non-conventional subtype of ab T lympho-
cytes. Contrary to conventional ab T cells that recognize
peptides presented by major histocompatibility complex
(MHC) molecules, NKT cells recognize lipids presented by
CD1d molecules. CD1d is a non-polymorphic MHC class I-like
molecule that is mainly expressed by dendritic cells (DCs) and
other APCs. The name NKT reflects one of their phenotypical
characteristics, as they express cell surface markers associ-
ated with the natural killer (NK) cell lineage, and particularly
CD161 in humans or NK1.1 in mice [10]. NKT cells are
remarkably conserved among mammals, suggesting a crucial
role in immunity [11]. Classically, NKT lymphocytes are
divided into three groups: iNKT, type II NKT, and NKT-like
lymphocytes, according to their antigenic specificity and the
expression of their T cell receptor (TCR) [12].iNKT cells represent the majority of NKT cells. They ex-
press a semi-invariant TCR a-chain, Va24Ja18 in humans and
Va14Ja18 in mice, associated to a restricted set of b-chains,
usually Vb11 in humans and Vb8, Vb7, or Vb2 in mice. They
recognize glycosphingolipids that are presented by CD1d,
such as glycosylceramides. A glycolipid isolated from a ma-
rine sponge, a-galactosylceramide (a-GalCer), has been shown
to be a potent activator of iNKT lymphocytes in bothmice and
humans. iNKT cells are either CD4þ or CD4CD8 double-
negative (DN). iNKT lymphocytes are considered as innate-
like T lymphocytes as they harbor an activated/memory
phenotype (CD69þ, CD44hi, CD62L), and are rapidly able to
produce large amounts of cytokines after the stimulation of
their TCR [13]. They can rapidly produce interleukin (IL)-4 and
interferon (IFN)-g, but also have cytotoxic effects. After acti-
vation, they interact with both innate and adaptive immune
systems, such asNK cells, DCs, T and B cells, through the rapid
production of Th1 and Th2 cytokines and the expression of
cell surface markers.
Type II NKT lymphocytes display both variable TCR-a and
-b chains. These cells do not recognize a-GalCer, but recog-
nize other antigens such as sulfatides and lysophosphati-
dylcholine and are also restricted by CD1d [14,15]. NKT-like
lymphocytes represent a more heterogeneous population,
with variant and invariant TCRs that express NK markers.
Among NKT-like is the recently described mucosal associated
invariant T (MAIT) cell, which TCR has the invariant Va7.2-
Ja33 chain in humans and Va19-Ja33 in mice. The ligands of
MAIT cells are metabolites from riboflavin synthesis by bac-
teria, modified by small molecules such as methylglyoxal
[16].
iNKT cells are a relatively rare lymphocyte population in
humans, as they represent less than 0.1% of peripheral white
blood cells. However, the development of Va14-Ja18 trans-
genic mice and the improvement of the specific detection of
iNKT cells with CD1dea-GalCer tetramers and 6B11 antibodies
have permitted a thorough study of these cells. iNKT cells
exert various functions in immunity. They play a key role in
the defense against pathogens such as bacteria, viruses, and
parasites [11,17e19]. They are also involved in defense against
tumors and metastases. Although iNKT cells have cytotoxic
properties, they are also major players in immune regulation.
Among other immune alterations, a defect of iNKT cells
has been observed and correlated with susceptibility to
various autoimmune diseases in mice and humans. In lpr
C57BL/6 mice, an animal model of systemic lupus erythema-
tosus, the development of autoimmunity is correlated with a
decrease of iNKT cell frequency [20,21]. A defect of frequency
and function of iNKT cells was observed in non-obese diabetic
(NOD) mice, as discussed below [22,23]. Similar iNKT cell ab-
normalities were also described in patients with autoimmune
diseases such as rheumatoid arthritis, systemic lupus ery-
thematosus, systemic sclerosis, and T1D [24e28].iNKT cells in T1D
The role of iNKT cells in the physiopathology of T1D has been
evidenced in animal models and suggested in humans [12].
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NOD mice, created in Japan in the early 1980s, are one of the
most studied animal models of T1D as they spontaneously
develop an autoimmune diabetes, very similar to human T1D
[3,6]. Like in human T1D, class II MHC plays a major role with
other genetic risk factors as well as with the environment.
Infiltration of pancreatic islets by hematopoietic cells, called
insulitis, begins at 3e5 weeks of age, causing b-cell destruc-
tion, which leads to diabetes at 4e6 months of age, mostly
among females [29]. This time delay suggests an immune
regulation that is temporarily able to protect b-cells. Charac-
terization of iNKT cells in NOD mice showed reduced fre-
quency and absolute number of iNKT lymphocytes in the
thymus and spleen compared to control mice (BALB/c, C57BL/
6), as early as 3 weeks of age [22,30]. These data, demon-
strating a very early defect in iNKT cells, first suggested that
this population could be involved in the genesis of the path-
ophysiology of the disease.A protective role in NOD mice
The protective role of iNKT cells against autoimmune dia-
betes was demonstrated in different experiments using the
NOD mouse model. CD1d-deficient NOD mice, lacking iNKT
cells, have a higher risk of developing diabetes and an earlier
onset [31]. On the contrary, Va14-Ja18 transgenic NOD mice,
possessing increased number of iNKT cells, present a
reduced incidence of diabetes [32]. They present a higher
frequency of functional iNKT cells in the spleen, as early as 3
weeks of age, before islet infiltration begins. The level of
protection of the different lines of transgenic mice was
correlated with the increase in iNKT cell numbers. Islet
infiltration at 12 weeks of age was present in transgenic
mice and their negative littermates, but was less invasive in
transgenic mice, evoking a better immunoregulation. These
concordant results suggest that iNKT cells can suppress
anti-islet autoreactive T cells.
Transfer experiences demonstrated the regulatory role of
iNKT cells. Whereas a co-transfer of Treg cells and BDC2.5 T
cells failed to protect NOD Severe Combined Immunodefi-
ciency (SCID) mice from diabetes, the co-transfer of iNKT cells
and BDC2.5 T cells or diabetogenic splenocytes from a non-
transgenic diabetic NOD mice into NOD SCID recipients
induced a strong protection from the disease [32,33]. Transfer
of splenocytes from BDC2.5 Ca/ mice into Ca/ NOD mice
induced diabetes in 80e100% of recipients, compared to less
than 10% when the recipient is a Va14 Ca/ NOD mice [34].
The protection afforded by iNKT cells was associated with the
inhibition of differentiation of BDC2.5 T cells into effector T
cells, and their decreased homing and local accumulation in
the pancreas. The immunoregulation of BDC2.5 T cells
occurred in pancreatic draining lymph nodes [34] as well as in
pancreas [3,33].
A similar protection was observed after specific stimula-
tion of iNKT cells with their specific ligands, principally a-
GalCer. Several groups have demonstrated that repeated in-
jections of the specific iNKT cell ligand a-GalCer decreaseinsulitis, and protect NOD mice from the development of
diabetes, in a CD1d-dependent manner [31,35]. The treatment
is more effective when started early, around the time when
insulitis begins [35].
These studies and others have demonstrated the protec-
tive role of iNKT cells in T1D mouse models, which involves
various regulatory mechanisms.Regulatory role through immune deviation and
cytokines
The presence of anti-islet autoreactive effector Th1 T cells is
associated with the development of autoimmune diabetes,
whereas a Th2 profile is frequently associated with its pro-
tection [3]. In NOD mice, it was evidenced that IL-4 exerts a
major negative effect on the progression to diabetes, as sys-
temic administration of IL-4 prevents diabetes onset [36]. If
iNKT cells are able to produce various amounts of cytokines,
including IFN-g and Granzyme B, they can also rapidly pro-
duce large amounts of IL-4. IL-4 produced by iNKT cells could
then play a major role in inhibiting Th1 autoimmune re-
sponses and inducing Th2 cell responses to islet antigens in
order to protect from diabetes onset, and their defect in T1D
could contribute to the pathogenesis of the disease.
Interestingly, iNKT lymphocytes in NOD mice present
functional deficiencies, as they produce lower levels of IL-4
after TCR stimulation, as early as 3 weeks of age, compared
to controlmice (BALB/c, C57BL/6) [22,30]. The correction of this
functional defect by the administration of exogenous IL-4 or
by the expression of IL-4 under the control of promoter insulin
prevented diabetes in NOD mice. Therefore, the defect in IL-4
production in NOD mice could be responsible, in part, for the
emergence of autoreactive anti-islet Th1 cells, leading to the
onset of insulitis and diabetes. Indeed, the protection against
diabetes in Va14-Ja18 transgenic NOD mice is not only asso-
ciated with an increased production of IL-4 in splenocytes, but
also in pancreatic islets, and a locally reduced production of
IFN-g within pancreas [32,37]. This protection is abolished
after the administration of antibodies neutralizing IL-4 and IL-
10 [37,38]. Similarly, after in vivo stimulation with a-GalCer,
iNKT cells from pancreatic lymph nodes (PLNs) of NOD mice
preferentially produce IL-4 [39]. This increase in IL-4 produc-
tion could be associated with the fact that a-GalCer treatment
preferentially expands CD4þ iNKT cells, which produce IL-4
rather than IFN-g [40].
In parallel, the up-regulation of CD1d expression in
pancreatic beta cells as a transgene protected NODmice from
autoimmune diabetes [41]. iNKT cells were not increased in
the lymphocyte infiltrates within pancreatic islets, but were
slightly increased in the PLNs. Moreover, protection from
diabetes was associated with an increase of IL-4 production in
the PLNs in these transgenic mice [41].
Other cytokines might be implicated in this immunoreg-
ulation process, and surprisingly, some studies showed that
IFN-g is necessary for the protective action of iNKT cells. The
regulation of BDC2.5 T cells by NKT cells was lost in a co-
transfer experiment in an NOD SCID mice, if the NKT cells
were obtained from a NOD Ifng/ mouse, and also if NKT
cells were transferred in an IFN-g receptor deficient host [33].
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g by iNKT cells was necessary to induce regulation by the
host, and not on autoreactive T cells. Similarly, upon infec-
tion with Coxsackie virus B4, IFN-g production by iNKT cell
induced the expression of indoleamine dioxygenase by
macrophages that became suppressive and inhibited patho-
genic T cell responses [42]. Thus, iNKT cells modulate APCs
and macrophages in an IFN-gedependent way, inducing
immune regulation.
Several studies highlighted that iNKT cells can also exert
an immunoregulatory role throughmechanisms independent
of cytokine production.iNKT cells can inhibit the differentiation of
autoreactive T cells into effector T cells
There are many evidences that autoreactive T cells are
essential for the development and progression of T1D. Several
studies tended to demonstrate that T1D could result from
defects in negative selection and peripheral tolerance induc-
tion [43]. b-cell antigens can be captured by pancreatic APCs
that secondarilymigrate in PLNs and can activate autoreactive
T cells. After activation, autoreactive anti-islet T cells can
migrate into the islets [44]. There, they can participate in the
destruction of b-cells through different mechanisms: through
direct MHC class I-mediated cytotoxicity; through the pro-
duction of pro-inflammatory cytokines, such as IFN-g, which
induce chemokine production, and by the expression of the
death receptor FAS by b-cells. IFN-g can also activate macro-
phages, increasing the inflammation in the islets and pro-
ducing cytokines including IL-1bwhich can directly induce the
apoptosis of b-cells [3].
Our group demonstrated that iNKT lymphocytes could
induce anergy of pathogenic T cells. First, we evidenced that
iNKT cells prevented diabetes development by inhibiting
pancreatic islet inflammation by autoreactive T cells, as Va14
Ca/ recipients of BDC2.5 naive T cells presented some levels
of peri-insulitis, but less inflammation and b-cell destruction
compared to Ca/ recipients [34]. iNKT cells did not affect the
activation and early proliferation of BDC2.5 T cells, but
inhibited their differentiation into IFN-g producing cells and
altered their capacity to sustain IL-2 production. At later
stages, it appeared that BDC2.5 T cells stimulated in the
presence of iNKT cells become anergic. Thus, iNKT cells can
protect from diabetes not only through Th2 bias induction but
also through the induction of anergy of autoreactive T cells.
Lack of IFN-g production by autoreactive T cells is the key for
the protection against diabetes.
Moreover, it was demonstrated that iNKT cells induce the
expansion of Treg cells. After transfer of BDC2.5 T cells, Treg
cells were found to be more frequent in the PLNs and
pancreatic islets of Va14 Ca/ recipients compared to Ca/
recipients [40]. This effect of iNKT cells on the expansion of
Treg cells was explored in proinsulin2/ NOD mice, an ani-
mal model developing accelerated diabetes. a-GalCer treat-
ment was demonstrated to induce strong Treg cell expansion
both in transferred BDC2.5 T cells and endogenous T cells, in
PLNs, and in pancreatic islets [40]. Moreover, these Treg cells
were more potent in suppressing naive T cell proliferation.This expansion was not secondary to the proliferation of the
initial Treg cell population, but rather to the conversion of
naive diabetogenic T cells into Treg cells. The induction of
anergy and the conversion of naive T cells into Treg cells are
associated with the induction of tolerogenic DCs by iNKT
cells.The dual role of iNKT cells in T1D
Pathogens, particularly viruses, can accelerate the develop-
ment of T1D, through a pancreatic tropism and the successive
inflammatory responses [45]. On the contrary, many studies
also described that infections, including viral infections, could
induce a protection against T1D [42,46]. iNKT cells exhibit dual
functions, as they are not only able to exert a tolerogenic
response in T1D, but also participate in responses against
some pathogens. During viral infections, iNKT cells are rapidly
activated and promptly produce Th1 cytokines. The question
is then: Could iNKT cells exert at the same time an anti-
infectious role and a tolerogenic one?
This was studied in the model of diabetes induced by the
lymphocyte choriomeningitis virus (LCMV). In this context,
iNKT cells not only play an active role in the antiviral
response, but also play a major role in the protection against
diabetes [46]. All NOD CD1d/ mice infected with LCMV
develop diabetes, whereas only 50% of NOD-infected mice
become diabetic and only 10% become diabetic if they are
treated with a-GalCer at the time of infection. Thus, the
LCMV infection can protect from diabetes in an iNKT-
dependent way. After infection, splenic iNKT cells activate
conventional DCs (cDCs), which produce IL-12 inducing a
strong anti-LCMV CD8þ response, which is necessary for the
elimination of the virus. In the pancreas, activated iNKT
cells do not interact with cDCs, but rather with plasmacy-
toid DCs (pDCs). The interaction between iNKT cells and
pDCs induces different actions. They promote the recruit-
ment of pDCs in the pancreatic islets and the local produc-
tion of IFN-a by pDCs, an antiviral cytokine, reducing the
viral-induced destruction of b-cells by anti-LCMV CD8 T
cells. The activated pDCs then migrate to the PLNs, where
they produce transforming growth factor-beta (TGF-b),
which induces the conversion of naive T lymphocytes into
Foxp3þ Treg cells. Thus, the interactions between iNKT
lymphocytes and pDCs both control the viral infection and
improve self-tolerance to b-cells, preventing the develop-
ment of diabetes. The induction of tolerogenic pDCs
required the production of IL-10 by iNKT cells and a cellecell
contact through the programmed cell death protein-1 (PD-1),
expressed by iNKT cells, and the programmed death-ligand
1 (PD-L1), expressed by pDCs [46].
Similarly, a-GalCer treatment induces tolerogenic DCs and
pDCs in the PLNs [40,47]. pDCs produce less IL-12, limiting the
Th1 bias, and have a reduced expression of the co-stimulatory
receptors CD80 and CD86. Thus, these pDCs can induce a
tolerogenic response or anergy. Activated pDCs license Treg
cells to migrate into pancreatic islets through the induction of
CXCR3 expression. Like in the LCMVmodel, this conversion is
dependent on TGF-b secretion [Fig. 1].
Fig. 1 e a-GalCer treatment protects from type 1 diabetes. After multi-dose a-GalCer injections, the infiltration of pancreatic
islets is reduced and NOD mice are protected from diabetes through different mechanisms. a-GalCer preferentially increases
CD4þ iNKT cell frequency, the subset producing IL-4. After a-GalCer treatment, iNKT17 cells produce less IL-17. Finally, this
treatment induces tolerogenic pDCs in pancreatic islets that secondarily migrate in PLNs. These tolerogenic pDCs, which
produce less IL-12 and more TGF-b, favor the anergy of autoreactive T cells and promote the conversion of naive autoreactive T
cells into Treg cells.
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IL-17 has recently been shown to be involved in the induction
of autoinflammatory and autoimmune diseases [48]. The first
identified source of IL-17 was CD4þ T cells that differentiated
into Th17 cells. In addition to these CD4þ T cells, recent
studies have demonstrated the production of IL-17 by other
cell types such as CD8þ T cells and gd T cells [49,50]. iNKT cells
are divided into subpopulations harboring different cell sur-
face markers and having various functions. A new subset of
iNKT cells has recently been described: iNKT17 cells [51,52].
This population of CD4NK1.1 iNKT cells produces high level
of IL-17 and low levels of IL-4 and IFN-g after stimulation with
its specific ligand. They constitutively express IL-23R andretinoic acid receptor-related orphan receptor gt (RORgt), and
IL-1b promotes IL-17 production [53]. Simoni et al. described
that iNKT17 cells could play a pathogenic role in the patho-
physiology of diabetes [54]. iNKT17 cells are four to six times
more frequent in the thymus, spleen, and PLNs from NOD
than from C57BL/6 control mice [55]. Moreover, they infiltrate
pancreatic islets, and are locally activated as they express IL-
17 predominantly in the pancreas in a CD1d-dependent
manner [54,56]. Transfer experiments of iNKT cell subsets
revealed the pathogenic role of iNKT17 cells in T1D. Transfer
of CD4 NK1.1 iNKT cells, containing iNKT17 cells, into NOD
Ca/ recipients co-transferred with anti-islet BDC2.5 T cells
increased the incidence of diabetes. The frequency of BDC2.5
T cells infiltrating the pancreas was increased in mice recon-
stituted with CD4 iNKT cells. The deleterious effect was
abolished after treatment with an anti-IL-17 antibody. In the
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with other cytokines such as IFN-g and IL-1b, induces induc-
ible nitric oxide synthase (iNOS) expression and NO produc-
tion. Then, IL-17 produced by iNKT17 cells could interact with
IFN-g produced by BDC2.5 T cells infiltrating the pancreas,
inducing the deleterious production of NO in pancreatic b-
cells, leading to their death. Thus, the iNKT17 cells exacerbate
the incidence of diabetes in NOD mouse models in an IL-
17edependent manner. Interestingly, a-GalCer treatment
suppresses the production of IL-17 by iNKT17 cells. Thus, it
could be anothermechanism by which a-GalCer protects NOD
mice from diabetes.The genetics of iNKT cells
The frequency of iNKT cells is already reduced in the thymus
of NODmice as compared to other strains of mice. The genetic
control of iNKT cell numbers has been explored by comparing
NOD and C57BL/6 mouse genome. Two loci were identified:
Nkt1 and Nkt2. Nkt1 is localized in the same region as one of
the NODmouse lupus susceptibility loci. Nkt2 is located in the
same region as Idd13, an NOD-derived diabetes susceptibility
locus [57]. This second identified region also includes a
peroxisome-associated protein. This finding suggests that
peroxisome could play a role in modulating glycolipid avail-
ability for CD1d presentation, influencing iNKT cell activation
and function [58]. Facciotti et al. demonstrated that mice
deficient in peroxysomal enzymes essential for the synthesis
of lipids had a significant alteration of iNKT cell frequency and
maturation [59].iNKT cells defects in T1D patients
A challenge in the study of iNKT cells in human blood is their
very low frequency, as they often represent less than 0.1% of
total peripheral blood lymphocytes. However, the develop-
ment of CD1dea-GalCer tetramers and anti-Va24-Ja18 anti-
bodies (6B11) allowed specific study of iNKT cells in humans
[60,61]. In humans, CD4þ and DN iNKT cells are functionally
distinct subsets, with Th2 cytokines being exclusively pro-
duced by the CD4þ subset, and they also harbor different
patterns of chemokine receptors and integrins, suggesting
different migratory properties [60,62]. Human iNKT cells were
demonstrated to be able to induce peripheral tolerance
through their interaction with monocytes, inducing their dif-
ferentiation into myeloid DCs. These myeloid DCs have a
tolerogenic phenotype, as they produce IL-10 and little or no
IL-12, and do not efficiently activate T lymphocyte prolifera-
tion or IFN-g production [63].
A defect in iNKT cells was observed in diverse autoimmune
diseases in humans [24,25]. However, human studies of iNKT
lymphocytes in T1D have yielded contradictory results, with
the frequencies of iNKT cells reported as increased, normal, or
decreased compared to healthy subjects, and also in terms of
functional defects [64]. A defect in iNKT cells in T1D patients
was first described in 1998: Wilson et al. reported that among
siblings discordant for diabetes, the diabetic siblings had
lower frequencies of DN Va24JaQþ T cells [65]. Moreover, theseVa24JaQþ T cells had a Th1 bias, as they lost the ability to
secrete IL-4, and mainly produced IFN-g after anti-CD3 stim-
ulation [65]. Similarly, Kukreja et al. described a reduced fre-
quency of iNKT cells not only among newly diagnosed and
long-diagnosed T1D patients, but also in some autoantibody-
positive non-diabetic patients, compared to healthy controls,
and iNKT cells of diabetic patients produced less IL-4 and also
less IFN-g [26]. This did not seem to be associated with a ge-
netic abnormality of the CD1d gene. Conversely, Lee et al.
found no difference in terms of frequency and function of
iNKT cells between diabetic patients, whether newly or long
diagnosed, and healthy controls [66]. More recently, Roman-
Gonzalez et al. found no differences between T1D patients
and healthy controls in terms of frequency of iNKT cells, iNKT
cell subsets, and production of Th1 or Th2 cytokines [64].
Finally, Li et al. found no differences in the frequency of iNKT
cells identified with tetramers between T1D patients and
controls, and did not detect iNKT17 cells in the peripheral
blood of both groups [56]. However, after expansionwith IL-1b,
the expanded iNKT cells from T1D patients comprised a
higher frequency of iNKT17 cells compared to healthy donors.
The differences found between the studies could be due to
the following: the large heterogeneity of iNKT cell frequencies
in humans; the low number of patients included; the various
methods of detection of iNKT cells, which are not very specific
in the early studies; and the different genetic backgrounds, as
the studies were conducted in different countries. “Different”
T1D could also explain these contradictory results: it pro-
gressively appears that there is no one T1D, but probably
different types, with different etiologies and different mech-
anisms leading to anti-islet auto-immunity, which could have
various consequences on the homeostasis of iNKT cells. Thus,
the role of iNKT cells in the development of human T1D is not
yet elucidated.
It would still be interesting to study these cells in the blood
of a larger cohort of patients with T1D and to compare the
characteristics of these cells at different stages of the disease:
before the onset, at recent onset, at early and late follow-up of
T1D. Moreover, characterization of the precise autoimmune
events happening within pancreatic islets and PLN is difficult
in humans. However, the network for pancreatic organ donors
with diabetes (nPOD network) allows the study of pancreas,
PLNs, and mesenteric lymph nodes from cadaveric organ do-
nors with T1D as well as from those who are islet autoanti-
body positive, and then could permit the study of iNKT cells in
those tissues. In 2005, Kent et al. found that in PLNs, iNKT cells
fromT1D secrete IFN-g and little IL-4, whereas iNKT cells from
healthy controls produce IL-4 and IFN-g after TCR activation
[67]. This could be further studied, in order to establish if iNKT
cell subsets are different in the PLNs of diabetic patients, and
could explain the production of different cytokines.iNKT cells in the prevention of T1D
As Treg cell restoration is a therapeutic approach in T1D, iNKT
cells could represent an interesting therapeutic target in order
to prevent or cure T1D. As previously described, a-Gal-
Cer(C26:0) multi-dose treatment was associated with a pro-
tection against diabetes in NOD mice. In humans, a-GalCer
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the protection from cancer [68]. Even though a-GalCer is used
in a soluble form to induce tolerogenic effect, other iNKT cell
agonistsmight bemore appropriate for therapeutic use in T1D
patients. a-GalCer is associatedwith some side effects inmice:
hepatitis and hepatocyte damage, enhanced allergic re-
sponses, and exacerbation of atherosclerosis. In addition, a
prolonged treatment seemed to be associatedwith a reduction
of iNKT cell frequency in the PLNs and could be associated
with a diminished efficacy. Thus, this ligand might not be the
most accurate and new iNKT cell agonists are being studied in
animal models.a-GalCer analogs
Structural modifications of a-GalCer influence the type of cy-
tokines produced by iNKT cells. An a-GalCer analog, C16:0,
only induces a low production of cytokines, including IL-4, by
iNKT cells, but is efficient to protect NOD mice from diabetes
[69]. This analog can activate tolerogenic DCs in PLNs and does
not transactivate NK cells. Moreover, C16:0 had a rapid kinetic
of induction and recovery of iNKT cell anergy. Thus, a thor-
ough study of the action of C16:0 on the development of T1D or
of other similar analogs could lead to the discovery of the
adequate iNKT cell ligand, which could prevent diabetes.Increasing the number of iNKT cells
In mice, increased numbers of iNKT cells, through a-GalCer
treatment, transgenic models, or through transfer experi-
ments, are associated with protection against diabetes.
Therefore, increasing the number of iNKT cells could be a
promising strategy in humans.
Some laboratories have developed in vitromethods in order
to increase the number of iNKT cells from peripheral blood. A
Phase 1 clinical trial showed that the injection of iNKT cells
expanded in vitro was well tolerated and without side effects
[70]. With this strategy, specific iNKT cell subsets, such as
CD4þ iNKT cells, which are protective in NOD mice could be
preferentially expanded and other pathogenic subsets, such
as iNKT17 cells, could be excluded.iNKT cells, environment, microbiota, and
metabolism
T1D is a multi-hit induced disease, in which genetics and
environment interact. The role of environment in the phys-
iopathology of the disease was first suggested by the incom-
plete concordance in identical twins. As environment plays a
key role, the role of the intestinal microbiota in autoimmunity
has recently acquired a growing interest, with evidence sug-
gesting its role in various autoimmune diseases, particularly
in the development of T1D. The intestinal microbiome rep-
resents a complex, symbiotic community that influences
human health and immune development. Patients with T1D
have an altered microbiota e those who eventually develop
T1D have higher levels of Bacteroidetes relative to Firmicutesapproximately 6 months after birth, the preceding clinical
signs of the disease, suggesting that this ratio of Bacteroidetes
to Firmicutes increases in autoimmune cases but declines in
those who do not develop the disease [71,72]. Several human
studies revealed mucosal alterations and increased intestinal
permeability in diabetic patients, beginning in the preclinical
phase of the disease [73]. These alterations could be due to
modification of the microbiota composition: bacterial genes
associated with the production of short-chain fatty acids and
gut integrity are less abundant in autoantibodies-positive
cases, with an increased risk for T1D, than in healthy con-
trols [72].
Therefore, we could propose that this modification of the
gut microbiota, associated with increased gut permeability
could allow the penetration of different glycolipids, which
could be ligands of iNKT cells and modulate their activation.
This differential activation in patients compared to healthy
subjects could modulate iNKT cell proliferation and functions
toward exhaustion, and could explain their reduced number
and loss of function. Conversely, a recent study performed in
mice revealed that sphingolipids produced by a symbiotic
microbe, Bacteroides fragilis, inhibit the proliferation of iNKT
cells in the gut of newborns and limit their local accumulation
[72]. Interestingly, these sphingolipids are more abundant in
T1D patients [74]. In humans, during the second trimester of
pregnancy, iNKT cells are present and mature in the small
intestine, underlining the potential link between gut micro-
biota and iNKT cell function in humans [75,76].
On the other hand, recent studies pointed out that micro-
biota could influence the host metabolism. A recent study by
Markle et al. evaluated the impact of gut microbiota in NOD
mice on the incidence of diabetes and the host metabolism
[77]. Whereas NODmice display a strong female-to-male bias,
germ-free NODmice have a similar T1D incidence, withmales
losing their relative protection. The relative protection of NOD
males appears to be dependent on the presence of some
commensal organisms that increase testosterone levels.
Indeed, male and female NOD mice harbor different gut
microbiota after puberty. The investigators evaluated the
impact of the gut microbiota on serum metabolites. Male and
female NOD mice present a distinct cluster of glycer-
ophospholipid and sphingolipid metabolites. A transfer of
male microbiota to female recipients increased their testos-
terone levels, modified the concentration of some glycer-
ophospholipids and sphingolipids, and protected them from
diabetes. Moreover, T cells frommalemicrobiotamanipulated
females had an impaired ability to transfer diabetes.
Thus, we can propose that the altered microbiota among
diabetic patients and at-risk patients could influence the host
metabolites and modify the proportion of some endogenous
glycerophospholipids, some of them being iNKT cell ligands.
Thus, alteration of these ligands could reduce iNKT stimula-
tion and proliferation, but could also induce a bias toward IL-
17 iNKT, with an ability to promote diabetes.Type II NKT cells in T1D
The immunoregulatory role of type II NKT cells in various
diseases is emerging. Type II NKT cells are CD1d-restricted,
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GalCer but recognize sulfatides. Type II NKT cells appear to be
less frequent than iNKT cells inmice, but aremore frequent in
humans. Their understanding in humans remains limited, but
animalmodels revealed that type II NKT cells are important in
antitumor immunity and in the protection against experi-
mental autoimmune encephalomyelitis [14,78].
Type II NKT cells can prevent the development of T1D.
Duarte et al. evidenced that overexpression of CD1d-restricted
TCR Va3.2 and Vb9, as transgenes in NODmice, induced a high
frequency of type II NKT cells producing high levels of IFN-g
and low levels of IL-4, and led to protection against T1D [79]. It
has been proposed that stimulation of type II NKT cells with
C24:0 or C24:1 sulfatides multi-dose treatment protected NOD
mice from diabetes in a CD1d-dependent manner [80]. The
activation of type II NKT cells could inhibit autoreactive dia-
betogenic T cell proliferation and cytokine production in the
PLNs. Type II NKT cells are enriched in PLNs, but no correla-
tion was found between NKT cell numbers and the severity of
diabetes [80]. Recently, Kadri et al. identified the mechanism
by which type II NKT cells could prevent the development of
T1D. In transfer experiments, CD4þ type II NKT cells down-
regulated the proliferation and differentiation of diabeto-
genic BDC2.5 T cells, thereby blocking diabetes development
[81]. The PD-1/PD-L1 pathway was essential for the immuno-
regulatory capacity of type II NKT cells. These results suggest
that type II NKT cells represent potential therapeutic targets to
prevent T1D in humans.iNKT cells in T2D
Converging studies unraveled the interactions between im-
mune system and metabolic abnormalities in T2D. In lean
state, macrophages are present within the adipose tissue,
presenting an anti-inflammatory phenotype that is referred to
as M2. Their differentiation and survival depends on IL-4 and
IL-13 [82]. During the development of obesity, they expand and
also switch toward an M1 pro-inflammatory phenotype. M2
macrophages promote local and systemic insulin sensitivity,
while M1 macrophages contribute to insulin resistance
through different pathways, for example, tumor necrosis
factor-alpha (TNF-a) produced by M1 macrophages inhibits
insulin-receptor signaling and impairs adipokine secretion
[83].
Recently, there has been a growing interest in the other
players of both innate and adaptive immune systems in
obesity and metabolic diseases. As iNKT cells have been
shown to be resident cells of adipose tissue and to recognize
glycolipids, they have been proposed to play a role in obesity-
induced inflammation and insulin resistance [84]. The ability
of iNKT cells to produce IL-4 could contribute to the activation
of M2 macrophages. In obese patients, omental and circu-
lating iNKT cell frequencies were lower than in healthy con-
trols [84]. Thus, the lack of iNKT cells could favor the switch of
macrophages toward M1 phenotype. Experiments in animal
models have led to contradictory results. Lynch et al. reported
that iNKT cell number is restored in the adipose tissue after
weight loss in humans and mice [85]. Mice lacking iNKT cells
show improved weight gain and insulin resistance on a high-fat diet, whereas adoptive transfer of iNKT cells into obese
mice or in vivo specific stimulation of iNKT cells with a-GalCer
decreases body fat and restores insulin sensitivity [85].
Moreover, Lynch et al. recently showed that iNKT cells in
adipose tissue produce IL-2, which increases Treg cell fre-
quency. These Treg cells produce IL-10 promoting the differ-
entiation ofM2macrophages [86]. Interestingly, Schipper et al.
described the beneficial role of iNKT cells against insulin
resistance in low-fat diet [87]. In contrast, Ohmura et al. found
opposite results: b2-microglobulin knock-out mice lacking
NKT cells presented reduced macrophage infiltration in the
adipose tissue and a better glucose tolerance, compared to
control mice, whereas a-GalCer injections exacerbated
glucose intolerance andmacrophage infiltration. According to
Mantell et al., NKT cell depletion in CD1d/mice on a high-fat
diet was not associated with an improved outcome in terms of
body weight and glucose tolerance, compared to wild-type
littermate controls [88,89]. These different experiments use
different protocols and different knock-out animal models.
Glucose and fatty acids increase the production of IL-1b in
pancreatic islets. The stress of b-cells following the need for
an increased insulin output could favor b-cell death and a
certain process of autoimmunity. iNKT cells could then have a
role as immunoregulators within the islets. Interestingly, in
the study of Simoni et al. about iNKT17 cells, where the pro-
duction of IL-17 by this subset seemed CD1d dependent, a
residual expression of IL-17 persisted in the absence of pe-
ripheral CD1d expression [54]. This suggested that local fac-
tors, such as IL-1b, could participate in the activation of
iNKT17 cells. Moreover, Li et al. demonstrated that IL-1b was
able to expand iNKT cells from the blood of T1D and T2D pa-
tients and healthy donors, and preferentially expanded
iNKT17 cells fromT1D patients [56]. Therefore, the presence of
IL-1b within the inflamed islets during obesity and T2D could
favor the expansion and activation of iNKT17 cells and pro-
mote the recruitment of auto-reactive T cells within the islets
[Fig. 2].Conclusion
This reviewhighlights the regulatory role of iNKT cells and the
emerging role of type II NKT cells in diabetes. Investigations in
NODmice have demonstrated the central role of iNKT cells in
the pathogenesis of T1D. Furthermore, new insights into the
role of microbiota and the interactions between metabolism
and the immune system suggest possible interactions with
NKT cells. The different results obtained in the human studies
underline the requirement for further studies, using specific
recognition of iNKT cells, in peripheral blood and tissues. New
advances in the study of these cells and the selection of new
agonists should permit the development of new therapeutic
strategies in order to prevent the development of T1D and
T2D, diseases with a growing incidence.Source of support
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